Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe COPD~* Smoking history of greater or equal to 10 pack-years~* Diagnosis of stable moderate to severe COPD as defined by the GOLD Guidelines~* Postbronchodilator FEV1 from 30% to 79% of predicted values, inclusive~* Postbronchodilator FEV1/FVC ratio \< 0.70~Exclusion Criteria:~* History or presence of asthma, allergic rhinitis, or exercise-induced bronchospasm~* Hospitalization for an acute COPD exacerbation in the 3 months prior to study entry~* Respiratory tract infection (including the upper respiratory tract) or COPD exacerbation in the 6 weeks prior to study entry~* Eosinophil count of at least 600 cells/mm3~* Long term oxygen therapy \> 15 hours a day

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Once-daily aclidinium/formoterol (Type: EXPERIMENTAL): Aclidinium bromide 200 µg/ formoterol fumarate 12 µg fixed-dose combination (FDC) once-daily in the morning, plus placebo once-daily in the evening
- Morning aclidinium/formoterol plus evening formoterol (Type: EXPERIMENTAL): Aclidinium bromide 200 µg/formoterol fumarate 12 µg FDC once-daily in the morning, plus formoterol fumarate 12µg once-daily in the evening
- Formoterol BID (Type: ACTIVE_COMPARATOR): Formoterol fumarate 12 µg twice-daily (BID)

Based on this trial design, predict the completion outcome and termination type (if applicable).